0001140361-14-027751.txt : 20140703 0001140361-14-027751.hdr.sgml : 20140703 20140703174600 ACCESSION NUMBER: 0001140361-14-027751 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140701 FILED AS OF DATE: 20140703 DATE AS OF CHANGE: 20140703 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9143477000 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sanofi CENTRAL INDEX KEY: 0001121404 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] STATE OF INCORPORATION: I0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 14961670 BUSINESS ADDRESS: STREET 1: 54 RUE LA BOETIE CITY: PARIS STATE: I0 ZIP: 75008 BUSINESS PHONE: 33153774400 MAIL ADDRESS: STREET 1: 54 RUE LA BOETIE CITY: PARIS STATE: I0 ZIP: 75008 FORMER NAME: FORMER CONFORMED NAME: SANOFI-AVENTIS DATE OF NAME CHANGE: 20040826 FORMER NAME: FORMER CONFORMED NAME: SANOFI SYNTHELABO SA DATE OF NAME CHANGE: 20010104 4 1 doc1.xml FORM 4 X0306 4 2014-07-01 0 0000872589 REGENERON PHARMACEUTICALS INC REGN 0001121404 Sanofi 54, RUE LA BOETIE PARIS I0 75008 FRANCE 0 0 1 0 Common Stock 2014-07-01 4 P 0 600 285.8900 A 20471841 I See note Common Stock 2014-07-01 4 P 0 930 287.0772 A 20472771 I See note Common Stock 2014-07-01 4 P 0 543 288.2412 A 20473314 I See note Common Stock 2014-07-01 4 P 0 689 289.3166 A 20474003 I See note Common Stock 2014-07-01 4 P 0 3513 292.9795 A 20477516 I See note Common Stock 2014-07-01 4 P 0 5001 294.2568 A 20482517 I See note Common Stock 2014-07-01 4 P 0 11155 295.0946 A 20493672 I See note Common Stock 2014-07-01 4 P 0 10463 296.3817 A 20504135 I See note Common Stock 2014-07-01 4 P 0 20472 297.2576 A 20524607 I See note Common Stock 2014-07-01 4 P 0 8238 298.1332 A 20532845 I See note Common Stock 2014-07-01 4 P 0 16683 299.1603 A 20549528 I See note Common Stock 2014-07-01 4 P 0 18074 300.2167 A 20567602 I See note Common Stock 2014-07-01 4 P 0 39530 301.2295 A 20607132 I See note Common Stock 2014-07-01 4 P 0 11932 302.3760 A 20619064 I See note Common Stock 2014-07-01 4 P 0 42419 303.2385 A 20661483 I See note Common Stock 2014-07-01 4 P 0 22158 304.0121 A 20683641 I See note The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). The shares were purchased pursuant to a plan intended to comply with Rule 10b5-1(c)(1)(i) under the Exchange Act, entered into with a broker on June 27, 2014. Purchase prices range from $285.55 to $286.25 per share, inclusive. Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 17,884,089 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuers Board of Directors. Purchase prices range from $286.69 to $287.50 per share, inclusive.. Purchase prices range from $287.74 to $288.72 per share, inclusive. Purchase prices range from $289.00 to $289.53 per share, inclusive. Purchase prices range from $292.50 to $293.38 per share, inclusive. Purchase prices range from $293.67 to $294.64 per share, inclusive. Purchase prices range from $294.68 to $295.53 per share, inclusive. Purchase prices range from $295.70 to $296.67 per share, inclusive. Purchase prices range from $296.72 to $297.69 per share, inclusive. Purchase prices range from $297.72 to $298.68 per share, inclusive. Purchase prices range from $298.73 to $299.72 per share, inclusive. Purchase prices range from $299.73 to $300.72 per share, inclusive. Purchase prices range from $300.73 to $301.70 per share, inclusive. Purchase prices range from $301.79 to $302.76 per share, inclusive. Purchase prices range from $302.80 to $303.79 per share, inclusive. Purchase prices range from $303.80 to $304.41 per share, inclusive. /s/ John Felitti, Associate Vice President, Corporate Law, Financial & Securities Law 2014-07-03